Everence Capital Management Inc. Makes New Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Everence Capital Management Inc. bought a new position in Pacira BioSciences, Inc. (NASDAQ:PCRXGet Rating) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,030 shares of the company’s stock, valued at approximately $308,000.

Several other large investors also recently made changes to their positions in the company. Baillie Gifford & Co. lifted its position in shares of Pacira BioSciences by 12.8% during the 4th quarter. Baillie Gifford & Co. now owns 2,355,240 shares of the company’s stock valued at $141,714,000 after acquiring an additional 267,433 shares during the last quarter. Paulson & CO. Inc. lifted its position in shares of Pacira BioSciences by 35.4% during the 4th quarter. Paulson & CO. Inc. now owns 1,705,599 shares of the company’s stock valued at $102,626,000 after acquiring an additional 446,081 shares during the last quarter. Loomis Sayles & Co. L P lifted its position in shares of Pacira BioSciences by 3.4% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,190,714 shares of the company’s stock valued at $71,645,000 after acquiring an additional 38,867 shares during the last quarter. Stephens Investment Management Group LLC lifted its position in shares of Pacira BioSciences by 16.8% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,138,810 shares of the company’s stock valued at $68,522,000 after acquiring an additional 163,928 shares during the last quarter. Finally, Frontier Capital Management Co. LLC lifted its position in shares of Pacira BioSciences by 17.1% during the 4th quarter. Frontier Capital Management Co. LLC now owns 929,871 shares of the company’s stock valued at $55,950,000 after acquiring an additional 135,927 shares during the last quarter.

Pacira BioSciences stock opened at $54.23 on Thursday. The company has a debt-to-equity ratio of 1.03, a current ratio of 2.19 and a quick ratio of 1.85. The company has a market capitalization of $2.46 billion, a price-to-earnings ratio of 64.56 and a beta of 0.89. Pacira BioSciences, Inc. has a one year low of $45.05 and a one year high of $82.16. The company’s fifty day moving average price is $64.68 and its two-hundred day moving average price is $65.48.

Pacira BioSciences (NASDAQ:PCRXGet Rating) last posted its earnings results on Wednesday, May 4th. The company reported $0.64 EPS for the quarter, missing the consensus estimate of $0.83 by ($0.19). The business had revenue of $157.99 million for the quarter, compared to analyst estimates of $155.08 million. Pacira BioSciences had a return on equity of 15.17% and a net margin of 6.62%. The company’s quarterly revenue was up 32.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.37 earnings per share. As a group, sell-side analysts anticipate that Pacira BioSciences, Inc. will post 2.8 earnings per share for the current year.

In other Pacira BioSciences news, insider Anthony Molloy sold 22,500 shares of the stock in a transaction on Wednesday, April 6th. The shares were sold at an average price of $76.42, for a total transaction of $1,719,450.00. Following the transaction, the insider now directly owns 17,550 shares of the company’s stock, valued at $1,341,171. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Mark Froimson sold 1,000 shares of the company’s stock in a transaction dated Monday, May 9th. The shares were sold at an average price of $59.37, for a total transaction of $59,370.00. Following the sale, the director now owns 4,908 shares of the company’s stock, valued at $291,387.96. The disclosure for this sale can be found here. Insiders have sold 95,693 shares of company stock worth $6,399,106 over the last three months. Company insiders own 6.10% of the company’s stock.

PCRX has been the subject of a number of research analyst reports. TheStreet lowered Pacira BioSciences from a “b-” rating to a “c” rating in a report on Thursday, February 24th. Northland Securities increased their target price on Pacira BioSciences from $61.00 to $67.00 in a report on Tuesday, March 1st. StockNews.com initiated coverage on Pacira BioSciences in a report on Thursday, March 31st. They issued a “hold” rating for the company. HC Wainwright increased their target price on Pacira BioSciences from $86.00 to $90.00 and gave the company a “buy” rating in a report on Friday, February 25th. Finally, Wedbush restated a “buy” rating and issued a $94.00 target price (down previously from $97.00) on shares of Pacira BioSciences in a report on Saturday, February 26th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Pacira BioSciences currently has a consensus rating of “Moderate Buy” and an average target price of $80.86.

Pacira BioSciences Company Profile (Get Rating)

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.

Read More

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRXGet Rating).

Institutional Ownership by Quarter for Pacira BioSciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.